Previous 10 | Next 10 |
home / stock / mvrbf / mvrbf news
Medivir AB ( OTC:MVRBF ): Q2 GAAP EPS of -SEK0.51. More news on: Medivir AB (publ), Medivir AB ADR, Earnings news and commentary, Tech stocks news, , Read more ...
Medivir AB ( OTC:MVRBF ) initiated with Buy rating at H.C. Wainwright. More news on: Medivir AB (publ), Cassava Sciences, Inc., CymaBay Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
STOCKHOLM , June 13, 2019 /PRNewswire/ -- Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR) today announces the results of an analysis of data from the first six patients with advanced cancer in the liver treated with increasing MIV-818 doses. The primary objective of the study is t...
STOCKHOLM , June 4, 2019 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announces that the company will participate at the 2019 BIO International Convention in Philadelphia , US. The presentation will take place at 11.30am local time on Wednesday, June 5, 2019 . Christina H...
STOCKHOLM , June 3, 2019 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today informs that new data from the phase I study of birinapant in combination with pembrolizumab (Keytruda®) was presented at an oral session on June 2nd at the American Society of Clinical Oncology (A...
STOCKHOLM , May 27, 2019 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announces that the company will participate at the Redeye Pre-ASCO Seminar in Stockholm . The presentation will take place at 9.15am on Tuesday, May 28, 2019 . Dr. Uli Hacksell, CEO of Medivir, will present t...
STOCKHOLM , May 13, 2019 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that positive data from the investigator-initiated study evaluating the effects of remetinostat in basal cell carcinoma (BCC) patients has been presented at the 2019 Society for Investigati...
STOCKHOLM , May 7, 2019 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that data from the investigator-initiated study evaluating the effects of remetinostat in basal cell carcinoma patients, will be presented during the 2019 Society for Investigative Derm...
STOCKHOLM , May 6, 2019 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today informs that new data from the phase II program of MIV-711, has been presented as a poster during the Osteoarthritis Research Society International (OARSI) world congress. The poster title was Safety and E...
Medivir AB ( OTC:MVRBF ): Q1 GAAP EPS of -SEK2.30. More news on: Medivir AB (publ), Medivir AB ADR, Earnings news and commentary, Tech stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Medivir B Company Name:
MVRBF Stock Symbol:
OTCMKTS Market:
MEDIVIR AB - INTERIM REPORT JANUARY - JUNE 2022 PR Newswire STOCKHOLM , Aug. 19, 2022 /PRNewswire/ -- The clinical development of fostrox remains the focus April - June Financial summary for the quarter Net turnover amoun...
Birinapant clinical study initiated by IGM Biosciences PR Newswire STOCKHOLM , Nov. 4, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR ) today announced that IGM Biosciences, Inc. has initiated its clinical study in solid cancers with birinapant (...
Medivir to present at the ProHearings shared Capital Markets Day PR Newswire STOCKHOLM , Oct. 11, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the ProHearings shared Capital Markets Day, Octo...